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Without any pharmaceutical intervention and vaccination, the only way to combat Coronavi-
rus Disease 2019 (COVID-19) is to slow down the spread of the disease by adopting non-
pharmaceutical public health interventions (PHIs). Patient isolation, lockdown, quarantine,
social distancing, changes in health care provision, and mass screening are the most com-
mon non-pharmaceutical PHIs to cope with the epidemic. However, there is neither system-
atic evidence on the effectiveness of non-pharmaceutical PHIs in controlling the COVID-19
nor on how these interventions work in different contexts. Therefore, in this study we will
address two main objectives: 1) to assess the effectiveness of the non-pharmaceutical PHIs
in controlling the spread of COVID-19 using a systematic review and meta-analyses; 2) to
explore why, how, and for whom these interventions work using a realist review.
Materials and methods
This review study has two main phases. In the first phase of this study, we will extract data
from two main types of studies including quasi-experimental studies (such as quasi-random-
ized trials, controlled before-after studies (CBAs) and interrupted time series studies (ITSs))
and observational studies (such as cohort, case-control, and cross-sectional studies), writ-
ten in the English language. We will explore effectiveness of the non-pharmaceutical PHIs
targeted either suppression or mitigation strategies (or a combination of both) in controlling
the COVID-19 epidemics in the community level. Effectiveness will be considered as the
changes in mortality rate, incidence rate, basic reproduction number rate, morbidity rate,
rates of hospitalization, rates of intensive care unit (ICU) hospitalization, and other health
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outcomes where possible. We will perform random-effects meta-analyses, if possible, using
CMA software. In the second phase, we will conduct a realist review to find out how, why, for
whom, and in what circumstances the non-pharmaceutical PHIs work. At the realist review,
we will identify and explore Context-Mechanism-Outcome configurations to provide a robust
explanation on the effectiveness of the interventions in different contexts using Pawson’s 5-
step realist review template including: "clarify scope; search for evidence; appraise primary
studies and extract data; synthesize evidence and draw conclusions; and disseminate,
implement and evaluate". Although the steps are presented in a linear manner, in practice,
we will follow them in iterative stages to fill any potential overlap.
Discussion
The findings of this research will provide a crucial insight into how and in which context the
non-pharmaceutical PHIs work in controlling the spread of COVID-19. Conducting a sys-
tematic review and meta-analysis in line with a realist review will allow us to draw a robust
conclusion on the effects and the way in which the interventions work. Understanding the
role of contextual factors in the effectiveness of non-pharmaceutical PHIs and the mecha-
nism of this process could enable policymakers to implement appropriate policies and man-




Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
outbreak in December 2019 in Wuhan- China and rapid spread all over the world [1], there
have been more than 4,500,000 confirmed cases and over 400,000 death by May 16, 2020. On
March 11, 2020, World Health Organization (WHO) declared SARS-CoV-2 outbreak as a
global pandemic [2]. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by
SARS-CoV-2. Currently, not only no effective immunization is available but also the risk of
the infection for the second or third times seems to be possible [2]. Additionally, there is no
certain treatment for COVID-19 and most of the available treatments are provided to control
the symptoms [3]. Currently, it seems that the best and most effective way to reduce the num-
ber of infected cases, as well as the number of COVID-19 related death, is to follow official
infection control measures and practice social distancing [2, 4].
COVID-19 disease burden has imposed an overwhelming pressure on health resources and
outcomes and economy of both High-Income Countries (HICs) and Low- and Middle-
Income Countries (LMICs) [5–7]. Without any pharmaceutical intervention, the only way to
slow down the spread of COVID-19 is reducing the interactions among the population [8]. In
the early days of the outbreak, some countries implemented a containment strategy [9]. How-
ever, the fast spread of the infection in those countries showed that this strategy is not very
effective [10]. Therefore, countries adopted more aggressive strategies such as mitigation and
suppression strategies. Some examples of such public health strategies include social distancing
(also known as physical distancing), contact tracing, travel restrictions, mass screening, and
lockdown [11, 12]. Whereas the main goal of mitigation strategies is to slow down the spread
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of the disease in order to reduce the burden by keeping the peak of hospitalizations (and
potential deaths) lower and more spread out so that resources aren’t overwhelmed, the main
goal of suppression strategies is to stop the spread of the virus within the community [13]. Sup-
pression is more forceful than mitigation and seeks to flatten the epidemic’s curve more rap-
idly [14]. Three main aims of both mitigation and suppression strategies include 1) flatten the
infection curve, 2) reduce the burden on hospitals/infrastructure, and 3) minimize the number
of cases and ultimately the number of deaths [15]. Effectiveness of such strategies could be
described in relation to the number of new cases detected, change in prevalence or cumulative
incidence of the disease, and rate of hospitalizations.
A various number of studies have been conducted to assess the effectiveness of different
public health strategies/interventions. For instance, a study by Marc Saez and colleagues
(2020) showed how a national lockdown helped to flatten the epidemic curve of COVID-19
[13]. Another study in China, regarding the effectiveness of quarantine and isolation, showed
that these interventions may need a longer period to be very effective [16]. Despite these stud-
ies, it is not systematically investigated if these interventions have been effective in controlling
the spread of the disease and why such interventions work in some regions and not in other
regions. Published articles have targeted only a specific aspect of the interventions. For exam-
ple, one study only compared the effectiveness of medical masks versus N95 respirators [17].
In another study, the researchers only assessed the effectiveness of quarantine among high-risk
individuals [18]. Although these studies are very useful in determining the effectiveness of a
specific intervention in controlling COVID-19 spread, they cannot explain the variation in
success of those strategies in different economic, cultural, or regional conditions. Moreover,
available studies have not comprehensively investigated the effectiveness of all implemented
public health interventions (PHIs). It is widely accepted that the success of a PHI is related to
the contextual factors [19, 20]. Understanding the impact of context is more important due to
the current situation and ongoing efforts to reduce the spread of COVID-19 by implementing
PHIs [8]. For example, during the 2003 Severe Acute Respiratory Syndrome Coronavirus
(SARS) outbreak in Singapore numerous non-pharmaceutical PHIs were implemented effec-
tively, including effective triage and infection control measures in health-care facilities, patient
isolation, contact tracing, and universal screening of school-aged children for fever [21]. Nev-
ertheless, the intensity of the impact of these measures was low in comparison to those that
have been adopted in China against COVID-19 [22, 23]. Differences in contextual factors such
as demography, social and political structure, and health systems’ readiness to deliver high-
quality services determine the effects of the non-pharmaceutical PHIs on the transmission of
COVID-19 [24]. However, there is neither systematic evidence on the effectiveness of non-
pharmaceutical PHIs in controlling the COVID-19 nor on how these interventions work in
different contexts. Therefore, in this study we will address two main objectives: 1) to assess the
effectiveness of the non-pharmaceutical PHIs in controlling the spread of COVID-19 using a
systematic review and meta-analyses; 2) to explore why, how, and for whom these interven-
tions work using a realist review.
Context in PHIs
There is a complexity with public health policies and interventions [25, 26], since their effec-
tiveness depends upon both the unique characteristics of interventions as well as the imple-
mentation context. Furthermore, interventions are adaptive, and they may change while
implementing in different contexts. The theories related to the implementation of PHIs pin-
pointed the importance of contextual factors [27]. According to these theories, intervention,
implementation, and context are extremely interconnected and influence one another [25].
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However, it is not easy to distinguish the boundaries of an intervention from its context,
because the boundaries are somewhat haphazard and there are necessarily long-lasting interac-
tions between them. Therefore, implementation of interventions within dynamic contexts
makes those boundaries difficult to be recognized [28]. This interaction between intervention
and context makes it difficult to discern between items belonging specifically to the interven-
tion and items belonging to the context. This differentiation is necessary for some reasons.
First, because of the dynamic nature of adapting an intervention, any changes should be taken
into account when evaluating them in a long period of implementation. Second, the interac-
tion between intervention and context is a determinant of the intervention’s effectiveness [29].
In fact, evaluation should be done to determine the interaction between the intervention items
and context items and to explore how they impact one another to create perceived outcomes
[28].
There are some examples of infectious disease epidemics that highlight the importance of
the role of context in the effectiveness of a PHI. For example, during the Zika outbreak in the
United States (US) and Brazil, the US experienced colossal political and economic challenges,
where Brazil, which had the highest number of Zika cases, experienced higher economic dis-
parity and serious shortages in sanitation and health care capacity. Using a social-ecological
framework, Linde-Arias et al. showed that interactions of macro, meso, and micro-level ele-
ments determine the reaction of the population to Zika. They also concluded that lack of trust
in governments made women more vulnerable because they did not completely follow the
health authorities’ instructions. This example indicates the role of political and social context
in the success of a PHI [30]. Effectiveness of a non-pharmaceutical PHI is tailored to changing
the behavior of the target population [31, 32]. That is, if people change their behavior in a way
to follow preventive measures in COVID-19 pandemics, the spread of the disease will slow
down; and at this regard, there are some theories that explain the behavior change mechanism
in the real world.
Why a realist review of context, and what is the contribution of this study?
Realist review is a robust review and synthesis method that allows reviewers to focus beyond
the randomized controlled trials (RCTs) as the basic sources of review documentation, by syn-
thesizing a variety of evidence types [33]. Addressing “how” and “why” questions is the focus
of a realist method, especially when exploring the outcomes of the PHIs [27]. The realist review
is a method of systematically synthesizing relevant evidence with the aim of the development
and refinement of theory by taking both context and outcomes into consideration. Opposed to
the conventional systematic review, in the realist review, studies are synthesized in an explana-
tory way rather than final judgment [27, 33].
The main role of the PHIs in regional and global levels is to control the infections such as
Ebola, SARS, Middle East respiratory syndrome coronavirus (MERS), and now COVID-19.
These epidemics or pandemics not only are associated with negative health outcomes in a
community but result in considerable economic losses as well. Patient isolation, quarantine,
lockdown, social distancing, changes in health-care provision (e.g. prioritizing patients for
receiving healthcare services in hospitals), mass screening, and vaccination are the most com-
mon public health initiatives to control infectious diseases like COVID-19 [34, 35]. In the
absence of vaccination and effective drugs, non-pharmaceutical PHIs are being considered as
the only way to control COVID-19. Although many countries like the UK and the US have
implemented multiple interventions to control the new epidemic [36, 37], there is no doubt
that the political, social, and geographical context has affected the success of any [38, 39]. Nev-
ertheless, it is not completely known which intervention(s), why, where, for whom, and how
PLOS ONE Non-pharmaceutical public health interventions against COVID-19
PLOS ONE | https://doi.org/10.1371/journal.pone.0239554 September 29, 2020 4 / 16
has been effective in slowing down the spread of COVID-19. Therefore, it is essentially impor-
tant to address the effectiveness of an intervention in its implementation context in order to
reduce the current uncertainty around public health initiatives.
Because of the complexity and dynamic nature of the implementation context, results of the
same public health measures differ when adopted in various settings. Therefore, it is highly
important to take the context into account when exploring the effectiveness of the interven-
tions [40]. Moreover, as mentioned above, context is often missing from studies on the effec-
tiveness of non-pharmaceutical PHIs against COVID-19. Using realist review we will show the
interactions between non-pharmaceutical PHIs, characteristics of context, and principal
mechanisms of change in controlling the spread of COVID-19. This realist review will answer
the questions including what non-pharmaceutical intervention/s work in controlling the
spread of COVID-19, in what circumstances, and for which group of population.
Materials and methods
This review study has two main phases. In the first phase, which is the quantitative part of the
study, we will conduct a systematic review to retrieve the robust, relevant studies on effects of
non-pharmaceutical PHIs on controlling the COVID-19 epidemics and will explore the scale
of the effects. In the second phase, which is the qualitative part, we will conduct a realist review
to find out how, why, for whom, and in what circumstances the interventions work in different
contexts.
Phase 1: Systematic review on effectiveness of non-pharmaceutical PHIs
The protocol of the systematic review adheres to the guidance provided in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement,
which is filled and provided as supporting information (S1 File). The systematic review will be
conducted from September to December 2020. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement will be followed to design and outline the
report [41].
Eligibility criteria for inclusion of studies. Population. Target population will be the
community population of the countries in which non-pharmaceutical PHIs have been imple-
mented to control and/or manage the COVID-19 during the pandemic.
Intervention. Non-pharmaceutical PHIs targeted either suppression or mitigation strategies
(or a combination of both) such as patient isolation, social distancing, quarantine, closing edu-
cational institutions, lockdown, border restrictions, mass screening, contact tracing, using per-
sonal protecting materials, and other similar interventions will be considered as interventions
of interest.
Comparator. We will have two types of comparators including:1) community population
before being involved in non-pharmaceutical PHIs, and 2) community population in which
no non-pharmaceutical PHIs have been implemented and only routine care has been provided
for infected cases.
Outcomes. Effectiveness of non-pharmaceutical PHIs will be assessed as desirable outcomes.
Effectiveness will be considered as the changes in mortality rate (confirmed COVID-19 deaths
in 100,000 population), incident rate (newly found cases per 100,000 population), morbidity
rate (confirmed COVID-19 cases per 100,000 population), and hospitalization rate (COVID-
19 hospitalization per 100,000 population). Intensive care unit (ICU) hospitalization rate
(COVID-19 ICU hospitalization per COVID-19 hospitalization) and basic reproduction num-
ber rate, and other health outcomes (based on the available data) will be considered as addi-
tional outcomes.
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Types of studies. Two main types of studies including quasi-experimental studies (such as
quasi-randomized trials, controlled before-after studies (CBAs), and interrupted time series
studies (ITSs)) and observational studies (such as cohort, case-control, and cross-sectional
studies) written in the English language will be included in the review.
Search strategy. Keywords were identified in three key domains including non-pharma-
ceutical interventions, coronavirus infectious disease, and effectiveness, using initial literature
reviews, the opinions of two experts on the subject, and the Medical Subject Heading (MeSH)
(Table 1). The search strategy was designed by a well-experienced medical librarian and will be
applied to databases. Pilot searches were conducted for each domain separately and for a com-
bination of all domains to make certain that the final search strategy was correctly adapted. A
sample search strategy for PubMed is available as supporting information (S2 File). Full search
strategies will be provided in the complete review.
Information sources. Major electronic databases will be searched (from December 2019
onwards) including, PubMed, Cochrane Library, Scopus, CINAHL, ProQuest, Embase, and
EconLit. Also, reference and citation lists of relevant studies (through Google Scholar cita-
tions), relevant reviews, clinical trial registers (Clinical trials.gov), gray literature (Gray.net),
preprint databases (such as medRxiv, bioRxiv, and arxiv.org.), the website of WHO, and other
relevant evidence will be reviewed carefully.
Data extraction. The search results will be imported in the Endnote program to manage
the studies and remove the duplicates. After pilot-test of the 10 percent of the studies by two of
the authors, the two authors will independently screen the title/abstracts carefully to retrieve
eligible studies. A data extraction form was designed based on the study of Tsou and colleagues
[42]. The designed extraction table contains the following items: bibliographic information,
methods, results, and discussion (S3 File). Three articles’ data will be extracted for testing the
validity of the data-extraction form. Afterward, the required information from each paper will
be extracted by two investigators, separately. In each stage of screening and data extraction,
disagreements will be solved by the decision of a third investigator. The PRISMA flow diagram
[41] will be used to report the screening and selection results.
Critical appraisal of individual sources of evidence. We will carefully and accurately
appraise the quality of eligible studies to assure the internal validity of the review results. In
order to explore the methodological quality and the risk of bias of the primary research papers,
two types of standardized quality assessment tools will be used based on the designs of the
studies. Cochrane Effective Practice and Organization of Practice (EPOC) Risk of Bias Tool
[43] will be used for appraising the quasi-experimental designs, such as quasi-randomized
Table 1. Primary search strategy/search concept grid for the systematic review.
Concept 1 Non-pharmaceutical public health interventions Concept 2 effectiveness Concept 3 Coronavirus disease 2019
patient isolation OR media report Effectiveness 2019 novel coronavirus disease
quarantine OR social shield Efficacy OR treatment outcome covid-19
social distance OR physical distance patient-relevant outcome sars-cov-2
travel ban OR travel restriction health outcome 2019 novel coronavirus infection
limit travel OR lockdown new cases 2019-ncov infection
Stay at home OR Avoid crowd Incidence OR prevalence coronavirus disease 2019 OR
contact tracing OR partner notification Hospitalization coronavirus disease-19
personal protecting material OR mask Reproduction number 2019-ncov disease
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trials, ITSs, and CBA studies. Suggested risk of bias criteria for studies with a separate control
group include: "random sequence generation; allocation concealment; baseline outcome mea-
surements similar; baseline characteristics similar, incomplete outcome data; knowledge of the
allocated interventions adequately prevented during the study; protection against contamina-
tion; selective outcome reporting; and other risks of bias". We will rate each item as low-risk,
high-risk, and unclear-risk [44]. Effective Public Health Practice Project (EPHPP) Quality
Assessment Tool for Quantitative Studies will be used for observational studies including
cohort, case control, and cross-sectional studies [45]. Previous studies have proved the content
and construct validity of the EPHPP [46] and have reported fair interrater agreement for indi-
vidual domains and excellent agreement for the final grade [47]. The EPHPP contains 20 items
in eight domains including "selection bias, study design, confounders, blinding, data collection
method, withdrawals and drop-outs, intervention integrity, and analyses". Raters will rate the
individual domains and the composite domain as strong, moderate, or weak [45]. Two of the
authors will independently appraise each eligible paper. Inter-rater agreement will be calcu-
lated by the intraclass correlation coefficient (ICC). Disagreements among the raters will be
solved by discussing the third author.
Data synthesis. Descriptive synthesis. A narrative explanation of the PICO and brief
results of each included paper will be arranged in a summary table and will be categorized into
bibliographic information, intervention, outcome measures, and main results. A second-tier
explanation of outcome measures will then be provided by details and validity of measures will
be examined. Considering each study’s perspective (health system or societal perspectives), fre-
quencies will be reported for each outcome measure to find any existing pattern in relation to
the context of using the measures.
Quantitative synthesis. Information extracted from each manuscript will be categorized
into the data extraction sheet to demonstrate the whole description of the included studies.
Due to the different interventions that we expect to include in the study, we will conduct analy-
sis separately for each type of intervention. Data points from primary observational studies
will be used to perform random-effects meta-analyses using CMA:2 (Comprehensive Meta-
Analysis) software. To explore the heterogeneity as a priori to the meta-analyses, summary
estimates will be predicted. For example, mean differences, standard mean differences, and
95% confidence interval, using the Hartung-Knapp-Sidik-Jonkman random-effects model
[48]. Using Forest plots, the extent of heterogeneity among studies will be visualized. Variance
between studies by I2 statistics (proportion of variation in prevalence estimates) will be com-
puted to quantify statistical heterogeneity (I2 ranges between 0 and 100%with values of 0–25%
demonstrate low heterogeneity, and 75–100% illustrate considerable heterogeneity). If I2 is
greater than 50%, the result of the study is considered as heterogeneous and the random effect
model will be used for analysis. The results of Tau2 and Cochran Q test will be reported to
indicate heterogeneity, in which estimate results with P-value of< 0.05 will be considered sta-
tistically significant. Funnel plot will be used to evaluate the possibility of publication bias.
Contingent on the number of eligible studies, we may further stratify the studies based on
design; and, where feasible, we will report the association measures including risk ratio, odds
ratio, prevalence ratio, hazard ratio, and incidence rate ratio. Furthermore, meta-analyses of
adjusted versus non-adjusted measures will be performed separately, if possible. Depending
on the data availability, subgroup analyses will be performed by country, gender, comorbidi-
ties, and other characteristics. We might perform sensitivity analysis to examine if there would
be differences in the synthesis results when all eligible studies are included compared to when
only high-quality once are included, and also, to examine that if the results would vary when
both published and unpublished studies are included compared to when only the published
studies are included.
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Meta-biases. Using suitable strategies, we will minimize the potential biases in the review
process. Unpublished papers including the preprints as well as the gray literature will be
included in the review. The potential publication biases will be explored by detecting and
assessing the magnitude of reporting biases using a Funnel plot. Furthermore, the quality of
the methodology of the systematic review will be assessed by the Assess the Methodology Qual-
ity of Systematic Reviews (AMSTAR) tool [49].
Phase 2: Realist review of the effectiveness of non-pharmaceutical PHIs
Given the complicated, dynamic, and multi-dimensional nature of non-pharmaceutical PHIs
[50] and lack of evidence on their effectiveness, we will perform a realist review to qualitatively
synthesize the relevant evidence in an explanatory way in order to indicate the mechanisms by
which these interventions succeed or fail.
Understanding which non-pharmaceutical PHI works successfully requires us to make theoret-
ically causal relationships [27]. Through the course of the realist review, hypotheses of interven-
tions are considered as ideas, beliefs, and desirable outcomes that define how those interventions
are supposed to work in the real world. When thinking realistically, programs are considered as
theories, and in realist reviews, the theories are explained by intertwined concepts of ‘Context’ (C),
‘Mechanism’ (M), and ‘Outcome’ (O) which are formulated as "C + M = O". To evaluate the effec-
tiveness of the interventions, we will explore their underlying mechanisms and their economic,
social, and geographical context to test CMO configurations. Mechanisms are the reactions caused
by the context, which either deliberately or haphazardly determine outcomes. Mechanisms could
result in different outcomes in different contexts. Each theory could encompasses a variety of
CMO configurations, and in this realist review, we will identify and explore CMO configurations
to provide a robust explanation on the effectiveness of the interventions in different contexts using
Pawson’s 5-step realist review template [27]. This template includes "clarify scope; search for evi-
dence; appraise primary studies and extract data; synthesize evidence and draw conclusions; and
disseminate, implement and evaluate". Although these steps are presented in a linear way, in prac-
tice, we will follow them in iterative stages to fill any potential overlap (Fig 1).
Step 1: Clarify scope. Following the guidance of Pawson [27] on realist review, we will
begin with clarifying and refining the research question to elicit the basic theories. In realist
reviews, in contrast to traditional systematic reviews, because of the dynamic, multifaceted fea-
tures of the interventions explored, the purpose of the review is explanatory rather than final
judgmental [51]. Using a limited number of combinations of keywords related to the imple-
mentation context in PHIs, we will conduct comprehensive searches in web-based electronic
databases to explore a variety range of key evidence to provide a general view of the topic area.
This initial scoping review of the evidence not only helps the investigators to get a profound
comprehension of the research problem but also will facilitate the determination of the rele-
vant ‘program theories’, which in this study is the explanations of how non-pharmaceutical
PHIs interact with the implementation context, and how and why these interventions are sup-
posed to succeed. The results of the scoping review at this stage will be a theoretical framework
for later steps of the realist review. The primary research question, when conducting the scop-
ing review, is "what non-pharmaceutical PHIs have been adapted to control the COVID-19
epidemics in the community level?". We also will address two sub-questions including: "in
what geographical, social, and political contexts have the non-pharmaceutical PHIs been
adapted to control the COVID-19 epidemics?"; and, "what outcomes were achieved when the
non-pharmaceutical PHIs were adapted to control the COVID-19 epidemics?".
Using the Joanna Briggs Institute (JBI) Manual For Evidence Synthesis [52], we developed
inclusion criteria for the scoping review as followings:
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Types of participants. The target participants in the scoping section is similar to the systematic
review and include the community population during the COVID-19 pandemics.
Concept. The overarching concept of interest is non-pharmaceutical PHIs that have been used
either as suppression or mitigation strategies to control the COVID-19 epidemics.
Context. We will focus on community level interventions in both HICs and LMICs.
Types of evidence sources. In this stage we will include a wide range of source of studies includ-
ing observational, quasi-experimental, and epidemiological studies, and reviews.
In order to conduct searches, a three-step search strategy will be used according to the rec-
ommendation of JBI [52]. The first step will be a primary limited search of two relevant online
databases including PubMed and Scopus. This primary search will be then followed by a
screening of the text words included in the title and abstract of the extracted papers as well as
the index terms used to characterize the manuscripts. Next, using all identified key terms, a
second search will be conducted across all relevant electronic databases for published and
Fig 1. Key steps in the realist review.
https://doi.org/10.1371/journal.pone.0239554.g001
PLOS ONE Non-pharmaceutical public health interventions against COVID-19
PLOS ONE | https://doi.org/10.1371/journal.pone.0239554 September 29, 2020 9 / 16
unpublished studies (such as gray literature and preprints). Thirdly, the reference and cita-
tion lists of the eligible studies will be searched for further sources. Using the eligibility cri-
teria, English language studies published since December 2019 will be retrieved and
imported in Endnote and duplicates will be removed. A pilot test of the source selectors will
be conducted prior to selecting the eligible studies. Using the eligibility criteria, three of the
team members will screen the titles/abstracts of a random sample of 25 studies. Disagree-
ments will be discussed by all team members and modifications will be made to the eligibil-
ity criteria where needed. If 75% (or higher) agreement is reached, two reviewers will start
screening and extracting eligible papers, independently, and any disagreements will be
solved by the decision of a third reviewer. In the scoping review, data charting (data extrac-
tion process) will provide a descriptive summary of the findings that fits the questions of the
scoping review. A draft charting form was adopted from the JBI methodology guidance for
scoping reviews and provided in supporting information (S4 File) [52]. The main informa-
tion on details and characteristics of the extracted evidence as well as details/results of the
evidence will be imported in the form. This might be improved in the review process and
the charting form would be updated accordingly. Prior to data charting, the two investiga-
tors will pilot-test the form. The final aim of charting the data is to recognize, specify, and
summarize the relevant evidence on the topic. The results of the scoping review will be pre-
sented in a tabular form as a map of the extracted data. Draft form of the tabular presenta-
tion of data for the scoping review is available as supporting information (S5 File). The draft
form would be refined and amended during the review process. Finally, a theoretical frame-
work will be developed to clarify the scope of the realist review and outline the later steps of
the realist review.
Step 2: Search for evidence. There are some differences in searching for relevant evidence
between realist reviews and traditional systematic reviews. In contrast to traditional systematic
reviews, in which specific types of evidence with specific methodology are selected, in realist
review, various sources of relevant information, which cover the topic of the study, make
reviewers follow a purposive sampling strategy. Moreover, in realist review, only primary stud-
ies, which contribute to the development of a complete picture of reality are included in the
synthesis. While other studies with similar results, which do not add any new element, are
excluded. By applying multiple search strategies with purposive sampling, reviewers could
answer questions or discover specific theories. Reviewers continue to purposively select studies
to recognize, test out, or refine the theories in an iterative way until reaching the saturation. As
a result, they could guarantee that adequate evidence has been collected to answer the research
questions [27, 40].
At this stage, we will carry out systematic searches to find relevant evidence such as process
evaluations and qualitative research, to discover and refine the program theories. The search
process will be developed gradually to find new and emerging evidence to cover all relevant
documents/articles that have addressed the theoretical needs of the research. This process will
be iterative and will be continued until reaching saturation, which means that all relevant evi-
dence has been found and included in the review to answer the research questions and refine
the theories. All scientific electronic databases and organizational websites will be searched
using multiple search strategies, which will be the combinations of the relevant search terms.
Furthermore, we will carefully screen the reference and citation lists of relevant studies as well
as gray literature to include as many different types of relevant documents as possible in the
review. Afterward, we will import all search results into EndNote software to manage them
and remove duplicates.
Our inclusion criteria include:
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• Nonpharmaceutical programs targeting the control of COVID-19 epidemics in the
community.
• Nonpharmaceutical programs targeting community behavior change mechanisms during
the COVID-19 epidemics.
• Nonpharmaceutical programs targeting community’s behavior during the COVID-19
epidemics.
Step 3: Appraise primary studies and extract data
At this stage, we will appraise studies based on two main criteria including relevance and
rigor. Unlike conventional systematic reviews, criteria of “relevance” for selecting evidence
is not about the relevance of the evidence to a specific topic; rather, it is about if the evidence
addresses the specific theory, which is under discovery. On the other hand, "rigor" indicates
if an explanation concluded by the original researcher is adequately robust to make a
methodologically acceptable and trustworthy contribution to the discovery of a specific the-
ory. Although "relevance" and "rigor" are not certain criteria to show the strength of an evi-
dence, they are appropriate to be used as "fitness for purpose criteria" in realist synthesis
[27].
Based on the emerging findings and the theory developed in step 1, we will develop
‘Bespoke’ data extraction forms [58] incorporating key elements and research questions. Dif-
ferent from data extraction sheets used in traditional systematic reviews, ‘Bespoke’ data extrac-
tion forms will be used mainly to collect information on contextual elements, mechanisms,
and outcomes, along with further information on non-pharmaceutical PHIs against COVID-
19 pandemics by two independent investigators. Desired outcomes will be changes in the
spread of disease and other health outcomes. In addition to information on intervention, con-
textual elements, mechanisms, and outcomes, we will extract bibliographic information on evi-
dence and strength and limitation of the study, where possible. To appraise the evidence for
relevance and rigor, we will use RAMESES (Realist And MEta-narrative Evidence Syntheses:
Evolving Standards) Quality Standards for Realist Synthesis [53] applying a ‘fitness for pur-
pose’ approach. Also, we may include the studies with weak methodologies in the synthesis if
they contain valuable, relevant information on the research theory. Two reviewers will extract
data and categorize them into tables as themes. Interpretation of data will be conducted in a
narrative format by judgment and reflection of all team members.
Step 4: Synthesize evidence and draw conclusions
In contrast to the systematic review and meta-analysis, no quantitative analysis will be con-
ducted at this stage and syntheses of evidence will be conducted narratively. The aim of this
step is to discover and refine the research theories to explore the interactions between contexts,
mechanisms, and outcomes [54]. Two reviewers will read the included studies carefully and
code their contents to identify contexts, mechanisms, outcomes, and CMO configurations. In
an iterative way, reviewers will search for repeated patterns of CMOs by comparing the evi-
dence. In the whole process of synthesizing the evidence, the authors will recall the research
questions and primary aim of the review in their mind to avoid digressing from the topic. At
the end of this stage, reviewers will explain two main issues in a narrative format; first, how,
and why non-pharmaceutical PHIs work in controlling the spread of COVID-19 within a spe-
cific context. Second, which contextual factors are most important, and how, when and for
whom they matter, regarding their impact on the implementation of non-pharmaceutical
PHIs.
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Step 5: Disseminate, implement, and evaluate
Finally, findings will be interpreted and presented as evidence-based, applied guidance to be
used by a wide range of stakeholders.
Discussion
The findings of this research will provide a crucial insight into how and in which context the
non-pharmaceutical PHIs work in controlling the spread of COVID-19. Understanding the
role of contextual factors in the effectiveness of non-pharmaceutical interventions and the
mechanism of this process could enable policymakers to implement appropriate policies and
manage the epidemics more efficiently.
Countries’ different approaches to manage COVID-19 outbreak and remarkably different
outcomes indicate the importance of studying the mechanisms in which non-pharmaceutical
PHIs work under the effects of contextual factors. Due to the novel and unknown features of
the COVID-19, it seems that a set of interventions in each setting need to be used to control
the epidemic [18]. Though lockdown, quarantine, contact tracing, and case isolation are pro-
posed as effective interventions to control the epidemic, they may result in different outcomes
in different contexts because of the particular features of the COVID-19 such as basic repro-
duction number, asymptomatic infected cases, and subclinical infection occurrence [55]. On
the other hand, contextual factors including economic situations, population density, social
norms, social interactions, social dynamics, and perceived risk of the disease, as well as system-
level factors such as government financial support and the population’s trust in government
[56] could influence the effectiveness of both suppression and mitigation strategies.
Comparing the mechanisms and contextual factors in effective management of the out-
break will help policymakers gain more evidence for future pandemics. This information will
be important for stakeholders to investigate interventions tailored to the context. A better
understanding of non-pharmaceutical PHIs will also inform policymakers about how to
develop and implement intervention at a local level. Moreover, conducting a systematic review
and meta-analysis in line with a realist review will allow us to draw a robust conclusion on the
effects of the interventions and the way in which the interventions work.
We predict some limitations with this study that should be pointed out. First, according to
the recent evidence, the same samples of the population have been included in some different
publications without providing obvious explanations for the duplicate reporting [57]. To
address this issue, we will make a special effort to identify the target population repeatedly
reported in different similar studies. Second, we will only include studies in English language,
so we will miss a large number of studies in a language other than English. Second, because of
the complex nature of the PHIs [50], we will perform meta-analysis separately for each inter-
vention (or a set of similar interventions). This may cause us not to be able to perform meta-
analysis for some types of intervention. Based on the guidance produced by the Cochrane Col-
laboration or the Centre for Reviews and Dissemination (CRD), we planned to conduct narra-
tive synthesis [58] and use Harvest plot method [59] for the condition in which performing
the meta-analysis is not possible because of the high heterogeneity of the studies. The Harvest
plot is a novel graphical method, which could be used for synthesizing information on PHIs by
including all relevant data where meta-analysis is not feasible or sensible [59].
Dissemination plan
Final reports of this study will be published in peer-reviewed journals as well as the PROS-
PERO website. All data will be available as supporting information once the review is
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completed. Also, brief findings will be presented in academic meetings and relevant profes-
sional assemblies.
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